ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025
Language English Country Great Britain, England Media print
Document type Journal Article, Practice Guideline
PubMed
40744042
DOI
10.1016/s1470-2045(25)00167-6
PII: S1470-2045(25)00167-6
Knihovny.cz E-resources
- MeSH
- Medical Oncology * standards MeSH
- Humans MeSH
- Endometrial Neoplasms * therapy pathology MeSH
- Neoplasm Staging MeSH
- Systematic Reviews as Topic MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Practice Guideline MeSH
In 2023, based on advances in the understanding of the pathological and molecular features of endometrial carcinoma, an updated International Federation of Gynaecology and Obstetrics (FIGO) staging system was published, aiming to better define prognostic groups and identify relevant treatment subgroups by including factors reflecting tumour biology (histological subtypes, lymphovascular space invasion, and molecular classification) alongside refinements of anatomical factors (peritoneal carcinomatosis and lymph node metastasis). As part of its mission to improve the quality of care for people with gynaecological cancers, the European Society of Gynaecological Oncology (ESGO), European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) updated the ESGO-ESTRO-ESP evidence-based guidelines published in 2021 by incorporating this revised FIGO staging and the large body of new evidence addressing the management of endometrial carcinoma. The development process of these guidelines was based on a systematic literature review and critical appraisal process involving an international multidisciplinary development group consisting of 30 experts from relevant disciplines (gynaecological oncology, radiation oncology, medical oncology, and pathology). A patient representative was also included. Before publication, the guidelines were reviewed by 225 independent international practitioners in cancer care delivery and three patient representatives from Asia, Europe, North Africa, North America, the Middle East, and South America to ensure a global perspective. These guidelines comprehensively cover diagnosis, management, follow-up, and patient education. Management includes surgical and adjuvant therapy according to the stage of the disease, and metastatic and recurrent disease. The management algorithms and the principles of radiotherapy and pathological evaluation are also defined.
Department of Gynecology and Gynecological Oncology Medical University of Vienna Vienna Austria
Department of Gynecology and Obstetrics Technische Universität Dresden Dresden Germany
Department of Medical Oncology Amsterdam University Medical Centers Amsterdam Netherlands
Department of Obstetrics and Gynecology Medical University Innsbruck Innsbruck Austria
Department of Oncology Rigshospitalet Copenhagen University Hospital Copenhagen Denmark
Department of Pathology Hospital Universitari Arnau de Vilanova Lleida Spain
Department of Pathology Leiden University Medical Center Leiden Netherlands
Department of Radiation Oncology Gustave Roussy Cancer Campus Villejuif France
Department of Radiation Oncology Leiden University Medical Center Leiden Netherlands
Department of Radiation Oncology Medical University of Vienna Vienna Austria
Department of Radiotherapy Erasmus MC Cancer Institute Rotterdam Netherlands
Department of Surgery and Cancer Faculty of Medicine Imperial College London London UK
Gynecologic Oncology Unit Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy
Gynecologic Service Department of Surgery Memorial Sloan Kettering Cancer Center New York NY USA
Histopathology and Molecular Diagnostics Azienda Ospedaliero Universitaria Careggi Florence Italy
Institut Bergonié Bordeaux France
Medical Oncology Department Cancer Center Clinica Universidad de Navarra Madrid Spain
Radiation Oncology Department Pitié Salpêtrière University Hospital Paris France
References provided by Crossref.org
